Overview

An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, multi-application pharmacokinetic study in pediatric subjects with tinea corporis.
Phase:
Phase 4
Details
Lead Sponsor:
Merz North America, Inc.
Merz Pharmaceuticals, LLC
Treatments:
Naftifine